When Pamela Keck, vice president of investor relations and corporate communications at German biotech Medigene, took up her role on February 1 this year, there was plenty to do. Her position had been unfilled for a number of months and executives were eager for her to hit the ground running. ‘There was no honeymoon period,’ she jokes to IR Magazine.
Thankfully, it wasn’t the first time Keck had arrived in a new IR role – far from it, in fact. Over the last 15 years, she has set up or taken over IR departments at several listed companies, both in . . .
Enjoy unlimited access to this, all deep dives and more – for free!
Log in or create your free My IR – Essentials account to:
- Get unlimited access to 50+ IR deep dives and best practice reports
- Benchmark your IR program instantly with our new tool
- Explore 100+ news analyses plus our exclusive CFO interviews
- Save favorites and get personalized content on your dashboard
- Enjoy 10% off all IR forums
